MH

Respiratory System: Chapter 21–23 Lecturr

Exam Context and Webinar Announcements

  • Sandra announced an EKG interpretation webinar with voice-over PowerPoint format; intent to help with reading EKGs and heart blocks.

  • Tandrika offered to share a recorded dysrhythmias session if given the link; facilitator agreed to distribute it after obtaining the recording.

  • Discussion of exam logistics: exam date is soon (next week). Instructions emphasize not sharing content prematurely and preparing with study questions likely to appear on the exam.

  • Listed topics/questions students anticipated on the exam: hemoglobin synthesis; red blood cell degradation; hemopoiesis; anemia; platelets; hypertension; acute arterial occlusion; deep vein thrombosis (DVT); oxygen/hemoglobin dissociation; myocytes; tuberculosis; cardiac action potential; neuromuscular disorders; mitral valve disease; congestive heart failure (CHF); second-degree heart block; shock types; calcium ions in myocardial contraction; conduction system; myocardial infarction; carbon dioxide transport; dispersion/conduction principles; respiratory anatomy and physiology; functional residual capacity; hypoxia; DVT; asthma; pulmonary function tests; cystic fibrosis; low cardiac output; and more.

  • Emphasis on connecting exam content to foundational physiology, clinical practice, and real-world relevance (e.g., recognizing when to escalate to emergency care).

  • Session ends with a plan to resume the last chapters and provide content lists for study.

Chapter 21: Respiratory Function and Alterations in Gas Exchange

  • Fetal development timeline

    • Lung development begins around day 26 of gestation.

    • By ~25 weeks gestation, fetal lungs are developed enough to allow respiration.

  • Anatomy: upper vs lower airways

    • Upper: nasopharynx, oral pharynx, large laryngeal/pharyngeal structures.

    • Lower: trachea, bronchi, bronchioles.

  • Pulmonary circulation and perfusion

    • Pulmonary circulation brings the entire cardiac output from the right ventricle to the alveoli for gas exchange via pulmonary arteries.

    • Blood becomes oxygenated in the alveoli and returns via pulmonary veins to the systemic circulation.

  • Aging and respiration

    • Aging leads to variations and changes in respiratory structure and function.

  • Lung volumes and capacities; dead space

    • Dead space is air in respiratory tract segments that does not participate in gas exchange:

    • Anatomic dead space

    • Physiologic dead space (composite of anatomic and alveolar dead space)

    • Alveolar dead space is air reaching alveoli that do not participate in gas exchange.

  • Minute ventilation and alveolar ventilation

    • Minute ventilation = volume of gas inhaled/exhaled per minute.

    • Alveolar ventilation concerns the portion participating in gas exchange; some air is wasted in dead space.

  • Gas exchange area and barriers

    • Diffusion occurs across the alveolar-capillary membrane; barriers include surfactant layer, alveolar membrane, interstitial fluid, and capillary membranes.

  • Surfactant

    • Surfactant reduces surface tension to prevent alveolar collapse (atelectasis).

    • Composition: ~90% lipid and ~10% protein.

  • Diffusion and concentration gradients

    • Gas diffusion is driven by concentration gradients (high to low): O2 moves from alveolar air (high O2) to blood (low O2); CO2 moves from blood (high CO2) to alveolar air (low CO2).

  • Transport of oxygen and carbon dioxide

    • Oxygen transport forms:

    • Dissolved in plasma: ~1.5\%

    • Bound to hemoglobin: ~98.5\%

    • Carbon dioxide transport forms:

    • Dissolved in plasma

    • Bound to hemoglobin (carbaminohemoglobin)

    • Bicarbonate ions \mathrm{HCO_3^-} (major form, via the carbonic acid-bicarbonate buffering system)

  • Hemoglobin and oxygen carrying capacity

    • Hemoglobin carries the majority of oxygen; dissolved O2 is a small fraction.

  • Partial pressures and diagnostic tests

    • Arterial blood gas (ABG) assesses O2 and CO2 levels and acid-base balance; used to diagnose respiratory failure and gas exchange abnormalities.

    • Chest X-ray and pulmonary function tests (PFT) assist in diagnosis and monitoring.

  • Respiratory control: neural and chemical regulation

    • Neural control centers: medulla oblongata and pons regulate breathing, heart rate, and blood pressure.

    • Medulla oblongata: primary autonomic control; integrates signals to breathing and heart function.

    • Pons: regulation of breathing patterns, sleep, and sensory input.

    • Neuroreceptors:

    • Central chemoreceptors respond to arterial CO2/pH changes; drive ventilation adjustments.

    • Peripheral chemoreceptors (carotid bodies, aortic bodies) respond to O2 and CO2 changes; particularly sensitive to hypoxemia.

    • Proprioceptors in skeletal muscles, tendons, joints influence movement and breathing.

    • Baroreceptors in the aortic arch and carotid sinus monitor BP and inform respiratory adjustments.

    • Hering-Breuer reflex: prevents overinflation of the lungs by signaling to stop inspiration.

    • Environmental factors and chemoreflexes influence respiration and pH homeostasis.

  • Pulmonary blood flow and ventilation distribution

    • Distribution of blood flow (perfusion) is uneven and affected by body position and exercise.

    • Ventilation distribution is also affected by gravity and body position; ventilation is greater at the base of the lungs when upright.

    • Ventilation-perfusion ratio ($V/Q$) assesses the efficiency of gas exchange; typically, ventilation and perfusion are matched in healthy lungs.

    • Hypoxic pulmonary vasoconstriction redirects blood flow away from poorly ventilated regions to better-ventilated regions to optimize gas exchange.

  • Gas exchange and diffusion barriers

    • Gas exchange mainly occurs by diffusion driven by a concentration gradient.

    • Diffusion can be impeded by barriers such as surfactant integrity, alveolar-capillary membrane thickness, and interstitial fluid.

  • Hypoxemia, hypoxia, and respiratory failure concepts

    • Hypoxemia: low blood oxygen levels; often reduces O2 delivery to tissues.

    • Hypoxia: tissue-level oxygen deficiency.

    • Acute respiratory failure: failure of gas exchange with hypoxemia and/or hypercapnia; clinical features include shortness of breath, cyanosis, confusion, and fatigue.

  • Respiratory function testing: spirometry and ventilatory metrics

    • Forced Vital Capacity (FVC): the amount of air that can be forcibly exhaled after full inspiration.

    • Tidal Volume (VT): normal volume of air displaced during normal breathing.

    • Inspiratory Reserve Volume (IRV): additional air that can be inhaled after a normal inspiration.

    • Expiratory Reserve Volume (ERV): additional air that can be exhaled after a normal expiration.

    • FVC = VT + IRV + ERV

    • Forced Expiratory Volume in 1 second (FEV1): volume exhaled in the first second of a forced expiration (key for obstructive disease assessment).

    • Total Lung Capacity (TLC): maximum amount of air the lungs can hold.

    • Functional Residual Capacity (FRC): the volume of air remaining in the lungs after a normal exhalation.

    • Bronchial provocation testing (e.g., methacholine): assesses airway hyperreactivity; methacholine is a muscarinic receptor agonist used to induce bronchospasm in controlled testing.

  • Practical clinical implications and exam relevance

    • Recognize differences between upper and lower airway involvement in respiratory disease.

    • Understand how V/Q mismatch drives symptoms and need for targeted therapy.

    • Identify when ABG and imaging are indicated, and how PFTs differentiate obstructive vs restrictive disorders.

    • Be able to interpret spirometry results and the significance of FVC, FEV1, and the FEV1/FVC ratio in diagnosis.

    • Grasp the role of surfactant and alveolar mechanics in preventing atelectasis and maintaining gas exchange.

    • Appreciate the importance of oxygen delivery, CO2 elimination, and acid-base balance in clinical assessment.

Chapter 22: Obstructive Pulmonary Disorders

  • Core concept

    • Obstructive disorders are characterized by increased airway resistance, which can be due to inflammation, airway wall changes, airway lumen obstruction, or external compression; many are reversible or variable in reversibility.

  • Asthma

    • Types and clinical variants

    • Adult-onset and pediatric-onset asthma; many pediatric cases improve with age.

    • Exercise-induced asthma; obesity-related asthma; eosinophilic asthma; neutrophilic asthma (a subset of severe asthma).

    • Pathogenesis and mechanisms

    • Denudation of airway epithelium with loss of ciliated cells; mucus hypersecretion; basement membrane thickening; edema; mucous plugging.

    • Inflammatory cell infiltration (neutrophils, eosinophils, lymphocytes) and mast cell activation.

    • IgE-mediated allergic mechanisms (atopy, allergic rhinitis, eczema) with genetic predisposition.

    • Allergen exposure triggers mast cell degranulation and release of mediators leading to bronchospasm and mucosal edema.

    • Clinical manifestations and assessment

    • Wheezing, chest tightness, dyspnea, cough; use of accessory muscles; intercostal retractions; distant breath sounds with inspiratory wheeze.

    • Peak Expiratory Flow Rate (PEFR) zones via spirometry: green (80–100%), yellow (50–79%), red (<50%), guiding urgency and therapy.

    • Status asthmaticus: life-threatening severe asthma unresponsive to bronchodilators; may require intubation.

    • Diagnosis and management

    • Diagnosis from history, physical exam, sputum examination, pulmonary function tests, blood gas analysis, chest X-ray.

    • Treatments: prevention and desensitization; prophylactic drugs; acute bronchodilators (e.g., short-acting beta-agonists); corticosteroids; oxygen therapy.

    • Maintenance inhalers for daily control; rescue inhalers for acute symptoms.

  • Acute bronchitis and chronic bronchitis

    • Acute bronchitis: acute inflammation of the trachea and bronchi; often viral or mycoplasma; cough is hallmark; usually self-limited; antibiotics only if bacterial infection suspected.

    • Chronic bronchitis: usually linked to smoking; chronic inflammation with goblet cell hyperplasia and mucus gland hypertrophy; productive cough; diagnosed by clinical symptoms and PFT.

  • Emphysema (COPD component)

    • Pathophysiology: destruction of alveolar walls due to proteolytic enzymes; alveolar surface area reduction; air trapping and hyperinflation; loss of elastic recoil.

    • Classifications by location: centriacinar (upper lobes, most common), panacinar (all lobes), paraseptal (peripheral).

    • Clinical features: progressive exertional dyspnea; barrel chest; clubbing (in some); weight loss; decreased breath sounds.

  • Bronchiectasis

    • Recurrent infections and inflammation lead to permanent dilation of medium-sized bronchi and bronchioles; copious purulent sputum; hemoptysis; chest radiography and CT important for diagnosis; treated with antibiotics, bronchodilators, chest physiotherapy, postural drainage.

  • Cystic fibrosis (CF)

    • Autosomal recessive CFTR gene mutation; multisystem involvement (pancreas, GI, lungs, sweat glands); copious thick mucus; recurrent infections; infertility in males;

    • Diagnosis: sweat test (pilocarpine iontophoresis to measure sweat chloride), genetic testing, chest imaging, pulmonary function tests.

    • Management: bronchodilators; chest physiotherapy; mucolytics (e.g., DNase); antibiotics for infections; nutritional support; potential lung transplant.

  • Acute tracheobronchial obstruction

    • Causes: foreign body aspiration, endotracheal tube malposition, laryngospasm, epiglottitis, trauma, smoke inhalation, post-surgical clots, tumors.

    • Presentation: absent or reduced air movement, inability to speak, tachycardia, cyanosis; requires rapid airway management (back blows, abdominal thrust, suctioning, possibly tracheostomy).

  • Epiglottitis and croup (laryngotracheobronchitis)

    • Epiglottitis: rapid onset; drooling, dysphagia, fever, inspiratory stridor; red/swollen epiglottis on exam; management may include airway support and antibiotics; Hib vaccine is preventive.

    • Croup (Laryngotracheobronchitis, “froupe syndrome”): barking cough with inspiratory stridor; management is supportive; antivirals or steroids may be used depending on severity; some cases may require supplemental oxygen or nebulized therapy.

  • Pneumonia and tuberculosis (TB) in the obstructive-relevant context

    • Pneumonia: alveolar airspaces become filled with exudate; bacterial, viral, or atypical etiologies; diagnosis via chest X-ray, sputum Gram stain, cultures, WBC count; treatment often begins with broad-spectrum antibiotics pending culture results.

    • TB: caused by Mycobacterium tuberculosis; dormancy possible (latent TB); Ghon complex (calcified TB complex) visible on chest radiograph; evaluation with purified protein derivative (PPD) skin test or Interferon-Gamma Release Assays (QuantiFERON); sputum culture for confirmation; multi-drug antimicrobial therapy for 6–9 months; infection control in healthcare settings.

  • Lung cancer (pulmonary malignancies)

    • Histologic types: small cell (oat cell) carcinoma and non-small cell subtypes (squamous cell, adenocarcinoma, large cell, bronchioloalveolar carcinoma).

    • Central vs peripheral origins; metastasis via lymphatics; diagnosis via imaging (CXR, CT), cytology/histology, PET-CT; treatment depends on stage and type (surgery, chemotherapy, radiation, targeted therapies).

Chapter 23: Restrictive Pulmonary Disorders

  • Core concept

    • Restrictive disorders are characterized by reduced lung volumes and capacities due to stiffness or loss of compliance, leading to impaired expansion of the lungs.

  • Fibrotic and interstitial lung diseases

    • Examples include sarcoidosis, hypersensitivity pneumonitis (expensive allergic alveolitis), occupational lung diseases (pneumoconiosis).

    • Hypersensitivity pneumonitis: inflammatory lung disease due to inhaled antigens; can progress to fibrosis.

    • Pneumocystis pneumonia (Pneumocystis jirovecii) and other parenchymal diseases (inhaled inorganic dusts) contribute to restrictive patterns.

  • Acute respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)

    • ARDS: diffuse alveolar damage with increased vascular permeability; severe hypoxemia refractory to oxygen therapy; diffuse interstitial/alveolar edema; mortality high; treated with mechanical ventilation and supportive care.

    • IRDS (hyaline membrane disease): primarily in preterm infants due to surfactant deficiency; presents with respiratory distress, hypoxemia, poor lung compliance; managed with surfactant replacement and respiratory support.

  • Pneumothorax and pleural effusions

    • Pneumothorax: air in pleural space causing lung collapse; spontaneous or traumatic; management includes observation, supplemental oxygen, chest tube drainage depending on size and symptoms.

    • Pleural effusion: accumulation of fluid in pleural space; evaluation with thoracentesis to analyze fluid; imaging with ultrasound/CT; treatment targets underlying cause and symptom relief.

  • Pneumonia and its restrictive associations

    • Pneumonia can present with restrictive-looking patterns depending on the extent of lung involvement and diffuse edema; management includes antibiotics (depending on pathogen), supportive care, and oxygen therapy.

  • Neuromuscular and obesity-related respiratory disorders

    • Neuromuscular diseases: polio, ALS, muscular dystrophies, Guillain-Barré syndrome, myasthenia gravis, kyphoscoliosis, ankylosing spondylitis; all can contribute to restrictive physiology by limiting chest wall/diaphragmatic movement.

    • Obesity hypoventilation syndrome: obesity with chronic hypoventilation, daytime somnolence, hypercapnia, hypoxemia, polycythemia; management includes weight loss, ventilatory support, and addressing comorbidities.

  • Obesity and weight management in respiratory disease

    • Obesity is a major contributor to respiratory morbidity; weight loss strategies (nutrition, exercise, pharmacologic agents like GLP-1 agonists) are part of comprehensive care; weight loss improves respiratory mechanics and reduces comorbidity burden.

  • Pneumonia and SARS/COVID context in restrictive/obstructive frameworks

    • SARS (2003) and COVID-19 (2019–present) are viral pneumonias with potential progression to ARDS and multi-organ involvement; clinical courses vary; vaccination and public health measures influence outcomes; clinical management emphasizes isolation, supportive care, and evolving guidelines.

  • Tuberculosis (TB) re-emphasis in restrictive context

    • TB is a chronic infectious process with granulomatous inflammation; epidemiology and infectious control considerations relevant to respiratory disorders; diagnosis via PPD/QuantiFERON and sputum cultures; standard treatment is prolonged multi-drug therapy.

  • Practical and clinical implications

    • Recognize that restrictive patterns can arise from interstitial disease, neuromuscular weakness, chest wall abnormalities, or obesity-related hypoventilation.

    • Diagnostic workup includes PFTs, imaging (X-ray, CT), ABG, and targeted laboratory tests to identify etiology.

    • Treatment prioritizes management of the underlying cause, supportive care, and preventive strategies (vaccination, smoking cessation, weight management).

Key Concepts, Formulas, and Terms to Remember (LaTeX formatting)

  • Gas exchange and diffusion barriers

    • Diffusion across the alveolar-capillary membrane is driven by a concentration gradient.

    • Surfactant reduces surface tension to prevent alveolar collapse; composition: \text{surfactant} \approx 90\%\,\text{lipid} + 10\%\,\text{protein}

  • Oxygen transport

    • Oxygen dissolved in plasma: \approx 1.5\%

    • Oxygen bound to hemoglobin: \approx 98.5\%

  • Carbon dioxide transport forms

    • Dissolved in plasma

    • Bound to hemoglobin as carbaminohemoglobin

    • Bicarbonate ion: \mathrm{HCO_3^-} (major buffering form in blood; part of the carbonic acid–bicarbonate system)

  • Hemodynamics and pressures (pulmonary circulation)

    • Pulmonary arterial pressure and pulmonary vascular resistance influence gas exchange and right heart load.

  • Ventilation-perfusion concepts

    • Ventilation-perfusion ratio: \dfrac{V}{Q}

    • Hypoxic pulmonary vasoconstriction diverts blood from poorly ventilated regions to better-ventilated regions to optimize gas exchange.

  • Spirometry and lung volumes (key equations)

    • Forced Vital Capacity: \text{FVC} = \text{VT} + \text{IRV} + \text{ERV}

    • Tidal Volume: \text{VT}

    • Inspiratory Reserve Volume: \text{IRV}

    • Expiratory Reserve Volume: \text{ERV}

    • Forced Expiratory Volume in 1 second: \text{FEV}_1

    • Total Lung Capacity: \text{TLC}

    • Functional Residual Capacity: \text{FRC}

  • Peak expiratory flow rate (PEFR) zones (ASTHMA management)

    • Green zone: 80\% \leq \text{PEFR} \leq 100\%

    • Yellow zone: 50\% \leq \text{PEFR} < 80\%

    • Red zone: \text{PEFR} < 50\% (medical emergency)

  • Oxygenation thresholds (ABG/pulse oximetry reference points)

    • Hypoxemia and tissue hypoxia occur when arterial oxygen is insufficient to meet metabolic needs; ABG measures P{\mathrm{O2}} and P{\mathrm{CO2}}, among others.

  • Key clinical concepts to connect

    • Hering-Breuer reflex: prevents overinflation of the lungs.

    • Central vs peripheral chemoreceptors: drive ventilation changes in response to CO2, O2, and pH changes.

    • Mucus hypersecretion and airway remodeling in asthma; IgE-mediated allergic pathways; role of eosinophils and mast cells in airway inflammation.

    • Surfactant deficiency in IRDS and the importance of alveolar stability for gas exchange.

    • TB tubercle and Ghon complex concepts in radiography and infection control.

  • Ethical and practical implications

    • Early identification and escalation to higher levels of care (ER/hospital) when patients present with potentially life-threatening respiratory symptoms (e.g., chest pain with dyspnea, cyanosis, hypoxemia).

    • Emphasis on patient education, smoking cessation, vaccination (e.g., Hib for epiglottitis; influenza vaccines; TB screening in high-risk populations).

    • Weight management and lifestyle interventions as core components of reducing respiratory disease burden (e.g., obesity-hypoventilation syndrome, COPD risk from smoking).

    • The clinician’s role in ensuring collaboration with specialists and appropriate use of diagnostic testing (PFTs, ABG, imaging) to guide therapy.

Quick Reference Summary

  • Surfactant and alveolar mechanics are essential to prevent atelectasis and maintain gas exchange.

  • Oxygen transport is mainly bound to hemoglobin; a small fraction is dissolved in plasma.

  • CO2 is transported in three forms: dissolved, carbaminohemoglobin, and bicarbonate (HCO3−).

  • The PEFR zones guide asthma management and escalation.

  • Pulmonary hypertension, PE/DVT, pneumonia, and TB require timely recognition and appropriate specialty referral when indicated.

  • Obstructive diseases (asthma, COPD spectrum with bronchitis, emphysema, bronchiectasis) involve reversible/irreversible airflow limitation and distinct pathophysiologies.

  • Restrictive diseases include interstitial fibrosis, ARDS/IRDS, neuromuscular causes, obesity-related hypoventilation, and pleural diseases.

  • Diagnostic tools: ABG, chest X-ray, CT, sputum culture, PFTs (spirometry), PEFR, and specialized tests (e.g., methacholine challenge).

  • Medical management emphasizes symptom control, prevention, and addressing underlying etiologies; emergency scenarios require rapid airway management and stabilization.

If you’d like, I can tailor these notes to a specific chapter or topic focus (e.g., only obstructive diseases, or only gas exchange physiology) or convert to a printable study guide with condensed bullet points and highlighted exam-style questions.